Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 9/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7240901 | 1.00 | TBXAS1 (0.55) | TBXAS1CYP19A1POLBMEN1LMNA | |
| Hydrochloric Acid SCHEMBL9795383 | 0.91 | CYP19A1 (0.54) | TBXAS1CYP19A1POLB | |
| Hydrochloric Acid SCHEMBL9795376 | 0.91 | CYP19A1 (0.54) | TBXAS1CYP19A1POLB | |
| SCHEMBL7245883 | 0.88 | CYP19A1 (0.47) | TBXAS1CYP19A1POLB | |
| SCHEMBL7708970 | 0.88 | CYP19A1 (0.47) | TBXAS1CYP19A1POLB | |
| SCHEMBL7245884 | 0.88 | CYP19A1 (0.47) | TBXAS1CYP19A1POLB | |
| SCHEMBL7241906 | 0.86 | CYP19A1 (0.53) | TBXAS1CYP19A1POLBMEN1KMT2A | |
| SCHEMBL7241907 | 0.86 | CYP19A1 (0.53) | TBXAS1CYP19A1POLBMEN1KMT2A | |
| SCHEMBL8228722 | 0.84 | CYP19A1 (0.45) | TBXAS1CYP19A1POLB | |
| SCHEMBL2352575 | 0.83 | CYP19A1 (0.49) | TBXAS1CYP19A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220495-A1 | Inhibitors of farnesyl protein transferase | ZENECA LIMITED AND ZENECA PHARMA S.A. | 2003-11-27 | — | — | US | disclosed |
| US-6414145-B1 | TREATING CANCER AND NEUROFIBROMATOSIS | ZENECA LIMITED (GB) | 2002-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220495-A1 | Inhibitors of farnesyl protein transferase | KRAS, FNTA, FNTB | TBXAS1 1494/4885CYP19A1 1303/4885POLB 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.